| Drug |
|
|---|
| Demeclocycline Tablet |
|
| Doxycycline Injection |
|
| Doxycycline Tablet |
|
| Tetracycline Capsule |
|
|
Tigecycline |
- Tigecycline use is
restricted to infectious disease specialists and will be non-formulary at this
time. Formulary status will be reevaluated in one year when sensitivity data
is available.
- The microbiology
department will obtain sensitivity panels and sensitivity testing is
recommended for all patients receiving Tigecycline. Tigecycline will not be
available for use until sensitivity testing can be performed. Note: The MIC
range for numerous bacteria is above the breakpoint for tigecycline.
- Antimicrobial therapy
should be directed by culture and sensitivity results.
- Patients who become
septic or develop septic shock have higher mortality rates when treated with
tigecycline (1.5%) versus comparator agents (0.5%). Alternative agents are
recommended.
- Tigecycline should not
be used in neutropenic, immunosuppressed patients, or patients with
endocarditis as it is bacteriostatic.
- Bactericidal agents are
preferred for the treatment of serious, life threatening infections.
- Tigecycline is
expensive, $88 per day, and should be reserved for conditions where less
expensive agents cannot be used. It is only available in an IV formulation.
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
